摘要
目的 :探讨替加环素治疗重症加强护理病房(ICU)腹腔感染患者的疗效及安全性。方法 :选取2016年2月—2018年2月我院重症医学科收治的108例腹腔感染患者为研究对象,按照随机数字表法分为观察组和对照组,各54例。对照组给予西医常规治疗,观察组在对照组基础上给予替加环素(首次剂量为100 mg,随后减为50 mg,将替加环素加入100 mL0.9%氯化钠注射液中静脉滴注,q12h)治疗。比较两组临床疗效、免疫功能、炎症指标水平。结果 :观察组总有效率为92.59%,大于对照组的77.78%,差异有统计学意义(P <0.05);治疗后观察组CD3+、CD4+、CD8+、CD4+/CD8+、自然杀伤细胞(NK)水平优于对照组,差异有统计学意义(P <0.05);治疗后观察组C反应蛋白(CRP)、外周血白细胞(WBC)、中性粒细胞(NE)水平均低于对照组,差异有统计学意义(P <0.05)。结论 :替加环素治疗ICU重症腹腔感染的效果显著,可改善患者免疫功能,降低炎症指标水平。
Objective:To investigate the effcacy and safety of tigecycline in the treatment of patients with abdominal infection in intensive care unit(ICU).Methods:108 patients with abdominal infection admitted to the department of critical care medicine in our hospital from February 2016 to February 2018 were selected as subjects investigated and randomly divided into an observation group and a control group,54 cases in each group.The patients in the control group were given conventional Western medicine treatment,and the patients in the observation group were given tigecycline treatment(the first dose was 100 mg,and then reduced to 50 mg,and tigecycline was added into 100 mL 0.9%sodium chloride injection for intravenous drip,q12h)on the basis of the control group.The clinical efficacy,immune functions and inflammatory index levels were compared between the two groups.Results:The total effective rate in the observation group was 92.59%,which was greater than 77.78%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD3+,CD4+,CD8+,CD4+/CD8+and natural killer(NK)cells in the observation group were better than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of C-reactive protein(CRP),peripheral blood leukocytes(WBC)and neutrophils(NE)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:Tigecycline is significantly effective in the treatment of severe abdominal infection in ICU,which can improve immune functions and reduce the level of inflammatory indexes.
作者
马尚超
Ma Shang-chao(Department of Critical Care Medicine,the First Affliated Hospital of Xinxiang Medical University,Xinxiang,Henan 453100,China)
出处
《中国合理用药探索》
CAS
2019年第1期86-88,92,共4页
Chinese Journal of Rational Drug Use